Difference between revisions of "Interferon alfa-2b (Intron-A)"
m |
m |
||
| Line 16: | Line 16: | ||
*[http://chemocare.com/chemotherapy/drug-info/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/intron-a-interferon-alfa-2b.aspx Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 6/4/1986: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| Line 71: | Line 74: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
| Line 79: | Line 81: | ||
[[Category:Neuroendocrine tumor medications]] | [[Category:Neuroendocrine tumor medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1986]] | ||
Revision as of 22:08, 8 November 2014
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Melanoma
- Multiple myeloma
- Neuroendocrine tumors
- Transplant conditioning regimens
Patient drug information
- Interferon alfa-2b (Intron-A) patient drug information (Chemocare)[4]
- Interferon alfa-2b (Intron-A) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/4/1986: Initial FDA approval
Also known as
Caution, may also contain names for interferon beta, interferon gamma, or interferon alfa-2a.
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Advaferon | Alfaferone | Berofor | Biogamma | Canferon A | |||
| Cytoferon | Egiferon | Feron | Fiblaferon | Frone | |||
| Finnferon-Alpha | Heberon Alfa R | Humoferon | IFN Alpha | Imufor | |||
| Imukin | INF | Inferax | Infergen | Inmutag | |||
| Interfero | Interferon Alfanative | Interferon Human | Interferon Leucocyticum | Interferon Lymphoblastoid | |||
| Interferonum Leucocyticum | Laroferon | Multiferon | Namalvin | OIF | |||
| Polyferon | Realdiron | Roceron-A | Sumiferon | Wellferon | |||